DOI QR코드

DOI QR Code

Clinical, Laboratory Biomarkers and Imaging Findings of Pancreatic Adenocarcinoma in Iran

  • Hadizadeh, Mohammad (Research Center for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Taleghani Hospital) ;
  • Padashi, Maryam (Research Center for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Taleghani Hospital) ;
  • Alizadeh, Amir Houshang Mohammad (Research Center for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Taleghani Hospital) ;
  • Zali, Mohammad Reza (Research Center for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Taleghani Hospital)
  • Published : 2014.05.30

Abstract

Background: Pancreatic cancer has a high mortality rate because it is usually diagnosed late. Since little is known about this cancer in Iran, with the aim of improving this knowledge deficiency, we evaluated clinical, laboratory biomarkers, imaging findings and treatment modalities in Iranian patients with pancreatic adenocarcinoma. Materials and Methods: 131 cases of pancreatic adenocarcinoma in 2010-2013 were obtained from the Taleghani Hospital Record Department. Cases confirmed by histopathology from CT-guided biopsy, EUS-FNA and surgery examination were included. We excluded those with incomplete medical records. Results: The study included 131 subjects between 24 and 97 years of age and a mean age of $63{\pm}13.4$ years. Eighty (61.1%) were male and 51 (38.9%) female. Previous history included diabetes mellitus in 36 (27.5%), alcohol drinking in 5 (3.9%), smoker in 28 (21.4%) and opium addiction in 13 (10%). The common presenting history included weight loss in 79 (60.3%), abdominal pain in 77 (58.8%), fever in 11 (8.4%), nausea in 30 (22.9%), jaundice in 72 (55%), pruritus in 52 (39.7) and anemia in 33 (25.2%). CA19-9 levels with cut offs of 50, 100 and 200 U/ml were increased in 81%, 72% and 66% of patients, respectively. Tumor staging was: stage I, 3 (2.3%); stage II, 10 (7.6%); stage III, 58 (44.3%); and stage IV, 60 (45.8%). From 45 patients, 17 received ERCP inserted metallic stents and 22 plastic stents, the remaining 6 failed that PTC was done. Whipple surgery and chemotherapy were conducted for 10 and 29 patients, respectively. Conclusions: This disease affected older people and there was a male preponderance. The commonest risk factors were diabetes mellitus, smoking and cholelithiasis. The majority of patients presented with loss of appetite, loss of weight, jaundice, abdominal pain and discomfort. Almost all presented at late stages of the disease so that curative surgery was impossible. Also chemotherapy was only performed in a few patients as a neoadjuant treatment.

Keywords

References

  1. Ahmadloo N, Bidouei F, et al (2010). Pancreatic cancer in southern Iran. IRCMJ, 12, 624-30.
  2. Barkin JJ, Goldstein JA (1999). Diagnostic approach to pancreatic cancer. Gastroenterol Clin N Am, 28, 709-19. https://doi.org/10.1016/S0889-8553(05)70083-2
  3. Bramhall SR, Allum WH, Jones AG, et al (1995). Treatment and survival in 13,560 patients with pancreatic cancer and incidence of the disease in the West Midlands: an epidemiological study. Br J Surg, 82, 111-5. https://doi.org/10.1002/bjs.1800820137
  4. Bray F, Sankila R, Ferlay J, Parkin DM (2002). Estimates of cancer incidence and mortality in Europein 1995. Eur J Cance, 38, 99-166. https://doi.org/10.1016/S0959-8049(01)00350-1
  5. American Cancer Society (2007) Cancer Facts, Figures. Inc 2007. Atlanta:American cancer society.
  6. Chiou WK, Huang BY, Chou WY, Weng HF, Lin JD (2011). Incidences of cancers in diabetic and non-diabetic hospitalized adults patients in Taiwan. Asian Pac J Cancer Prev, 12, 1577-81.
  7. Current Situation in the Islamic Republic of Iran (2009). Govaresh\Vol.14, No.3, Autumn; 189-97.
  8. Canyilmaz E, Serdar L, Uslu GH, et al (2013). Evaluation of prognostic factors and survival results in pancreatic carcinomas in Turkey. Asian Pac J Cancer Prev, 14, 6573-8. https://doi.org/10.7314/APJCP.2013.14.11.6573
  9. Engin H, Bilir C, Ustun H, Gokmen A (2012). ABO blood group and risk of pancreatic cancer in a turkish population in western blacksea region. Asian Pac J Cancer Prev, 13, 131-3. https://doi.org/10.7314/APJCP.2012.13.1.131
  10. Farzin L, Moassesi ME (2013). Evaluation of trace elements in pancreatic cancer patients in Iran. Middle East J Cancer, 4, 79-85.
  11. Fotouhi A, Khabazkhoob M, Hashemi H, Mohammad K (2009). The prevalence of cigarette smoking in residents of Tehran. Arch Iran Med, 12, 358-64.
  12. Ghadirian P, Lynch HT, Krewski D (2003). Epidemiology of pancreatic cancer: an overview. Cancer Detection Prev, 27, 87-93. https://doi.org/10.1016/S0361-090X(03)00002-3
  13. Helmstaedter L, Riemann JF (2008). Pancreatic cancer EUS and early diagnosis. Arch Surg, 393, 923-27. https://doi.org/10.1007/s00423-007-0275-1
  14. Huxley R, Ansary-Moghaddam A, de Gonzalez AB, et al (2005). Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer, 92, 2076-83. https://doi.org/10.1038/sj.bjc.6602619
  15. Inoue M, Tajima K, Takezaki T, et al (2003). Epidemiology of pancreatic cancer in Japan: a nested case-control study from the hospitalbased epidemiologic research program at Aichi cancer center (HERPACC). Int J Epidemiol, 32, 257-62. https://doi.org/10.1093/ije/dyg062
  16. Inoue M, Yamamoto S, Kurahashi N, et al (2008). Daily total physical activity level and total cancer risk in men and women: results from a large-scale population-based cohort study in Japan. Am J Epidemiol, 168, 391-403. https://doi.org/10.1093/aje/kwn146
  17. Jamali A, Kamgar M, Massarrat S, et al (2013). The Incidence and survival rate of population-based pancreatic cancer patients: Shanghai cancer registry 2004-2009. PLOS ONE, 8, e76052. https://doi.org/10.1371/journal.pone.0076052
  18. Jiao L, Mitrou PN, Reedy J, et al (2009). A combined healthy lifestyle score and risk of pancreatic cancer in a large cohort study. Arch Intern Med, 169, 764-70. https://doi.org/10.1001/archinternmed.2009.46
  19. Kruk J, Czerniak U (2013). Physical activity and its relation to cancer risk: updating the evidence. Asian Pac J Cancer Prev, 14, 3993-4003. https://doi.org/10.7314/APJCP.2013.14.7.3993
  20. Lei Li, Wu B, Yang LB, Yin GC, Liu JY (2013). Chronic hepatitis B virus infection and risk of pancreatic cancer: a metaanalysis. Asian Pac J Cancer Prev, 14, 275-9. https://doi.org/10.7314/APJCP.2013.14.1.275
  21. Lin Y, Tamakoshi A, Kawamura T, et al (2002) A prospective cohort study of cigarette smoking and pancreatic cancer in Japan. Cancer Causes Control, 13, 249-54. https://doi.org/10.1023/A:1015052710213
  22. Lin Y, Tamakoshi A, Kawamura T, et al (2001). An epidemiological overview of environmental and genetic factors of pancreatic cancer. Asian Pac J Cancer Prev, 2, 271-80.
  23. Lowenfels AB, Maisonneuve P (2002). Epidemiology and etiological factors of pancreatic cancer. Hematol Oncol Clin N Am, 16, 1-16. https://doi.org/10.1016/S0889-8588(01)00003-X
  24. Matsuo K, Ito H, Wakai K, et al (2011). Cigarette smoking and pancreas cancer risk: an evaluation based on a systematic review of epidemiologic evidence in the Japanese population. Jpn J Clin Oncol, 41, 1292-302. https://doi.org/10.1093/jjco/hyr141
  25. Momi N, Kaur S, Ponnusamy MP, et al (2012). Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis. Carcinogenesis, 33, 1617-28. https://doi.org/10.1093/carcin/bgs186
  26. Murr MM, Sarr MG, Oishi AJ, van Heerden JA (1994). Pancreatic cancer. Ca Cancer J Clin, 44, 304-18. https://doi.org/10.3322/canjclin.44.5.304
  27. Nakao M, Hosono S, Ito H, et al (2013). Cigarette smoking and pancreatic cancer risk: a revisit with an assessment of the nicotine dependence phenotype. Asian Pac J Cancer Prev, 14, 4409-13. https://doi.org/10.7314/APJCP.2013.14.7.4409
  28. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancerstatistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  29. Schenk M, Schwartz AG, O'Neal E, et al (2001). Familial risk of pancreatic cancer. J Natl Cancer Inst, 93, 640-4. https://doi.org/10.1093/jnci/93.8.640
  30. Stevens RJ, Roddam AW, Spencer EA, et al (2009). Factors associated with incident and fatal pancreatic cancer in a cohort of middle-aged women. Int J Cancer, 124, 2400-5. https://doi.org/10.1002/ijc.24196
  31. Taghavi A, Fazeli Z, Vahedi M, et al (2011) Pancreatic cancer mortality and misclassification-bayesian analysis Asian Pac J Cancer Prev, 12, 2271-4.
  32. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (2011). Pancreatic cancer. Lancet, 378, 607-20. https://doi.org/10.1016/S0140-6736(10)62307-0
  33. Wang Z, Song ZF, Xie RM, et al (2013). Analysis of death causes of in-patients with malignant tumors in Sichuan cancer hospital of China from 2002 to 2012. Asian Pac J Cancer Prev, 14, 4399-402. https://doi.org/10.7314/APJCP.2013.14.7.4399
  34. Woo SM, Joo J, Lee WJ, et al (2013). Risk of pancreatic cancer in relation to ABO blood group and hepatitis C virus infection in Korea. J Korean Med Sci, 28, 247-51.
  35. Zahir ST, Arjmand A, Kargar S, Neishaboury M (2013). Incidence and trends of malignant and benign pancreatic lesions in Yazd, Iran between 2001 and 2011. Asian Pac J Cancer Prev, 14, 2631-5. https://doi.org/10.7314/APJCP.2013.14.4.2631

Cited by

  1. Epidemiologic Data, Tumor Size, Histologic Tumor Type and Grade, Pathologic Staging and Follow Up in Cancers of the Ampullary Region and Head of Pancreas in 311 Whipple Resection Specimens of Pakistani Patients vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7541